{"id":31036,"date":"2025-05-29T15:55:55","date_gmt":"2025-05-29T20:55:55","guid":{"rendered":"https:\/\/myeloma.ca\/?p=31036"},"modified":"2025-05-29T15:57:41","modified_gmt":"2025-05-29T20:57:41","slug":"derniere-recherche-sur-le-myelome","status":"publish","type":"post","link":"https:\/\/myeloma.ca\/fr\/2025\/05\/29\/derniere-recherche-sur-le-myelome\/","title":{"rendered":"Derni\u00e8re recherche sur le my\u00e9lome"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.mdpi.com\/1718-7729\/32\/4\/238\"><em>Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma<\/em><\/a> [Perspectives sur l\u2019administration en milieu ambulatoire des anticorps bisp\u00e9cifiques ciblant les cellules T dans le traitement du my\u00e9lome multiple] (en anglais).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ces recommandations d\u2019experts ont \u00e9t\u00e9 d\u00e9velopp\u00e9es pour aider les cliniciens \u00e0 mieux suivre les patients recevant des traitements \u00e0 base d\u2019anticorps bisp\u00e9cifiques ciblant les cellules T (p. ex., des agents tels que teclistamab et elranatamab) et pour soutenir les \u00e9tablissements dans la mise en place de protocoles facilitant leur administration en milieu ambulatoire.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma [Perspectives sur l\u2019administration en milieu ambulatoire des anticorps bisp\u00e9cifiques ciblant les cellules T dans le traitement du my\u00e9lome multiple] (en anglais). Ces recommandations d\u2019experts ont \u00e9t\u00e9 d\u00e9velopp\u00e9es pour aider les cliniciens \u00e0 mieux suivre les patients recevant des traitements \u00e0 base d\u2019anticorps bisp\u00e9cifiques [&hellip;]<\/p>\n","protected":false},"author":10,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[88,53],"tags":[],"class_list":["post-31036","post","type-post","status-publish","format-standard","hentry","category-actualites","category-actualites-et-evenement"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/31036","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/comments?post=31036"}],"version-history":[{"count":1,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/31036\/revisions"}],"predecessor-version":[{"id":31037,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/31036\/revisions\/31037"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=31036"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/categories?post=31036"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/tags?post=31036"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}